CONSOLIDATED FINANCIAL REPORT
For the First Quarter of Fiscal 2011
(Fiscal Year Ending March 31, 2012, Japan Standard)

August 2, 2011

Eisai Co., Ltd. — Stock exchange listings: Tokyo, Osaka
TSE Code: 4523 — URL http://www.eisai.co.jp
Representative: Haruo Naito, Director, President & CEO
Contact: YutakaTsuchiya, Executive Vice President, Public Affairs — Telephone: +81-3-3817-5120

Expected date of quarterly report submission: August 8, 2011
Expected date of dividend payment commencement: -
Preparation of quarterly supplementary explanatory material: Yes
Quarterly results briefing held: Yes

(Figures are rounded down to the nearest million yen unless otherwise stated)

1. Consolidated Financial Results for the First Quarter of Fiscal 2011 (April 1, 2011 to June 30, 2011)

(1) Consolidated Operating Results (cumulative)

(Percentage figures show year-on-year change)

	Net sales		Operating income		Ordinary income		Net income	
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%
1Q Fiscal 2011	167,292	-18.2	22,215	-32.2	21,158	-29.9	13,505	-28.1
1Q Fiscal 2010	204,463	+5.0	32,773	+35.7	30,167	+30.2	18,789	+14.9

(Note) Comprehensive income: 1Q Fiscal 2011 ¥4,739 million (- %) 1Q Fiscal 2010 -¥823 million (- %)

	Basic earnings per share	Diluted earnings per share
	(¥)	(¥)
1Q Fiscal 2011	47.39	47.39
1Q Fiscal 2010	65.94	65.94

(2) Consolidated Financial Position

	Total assets	Equity	Shareholder's equity ratio	Book value per share
	(¥ million)	(¥ million)	%	(¥)
As of June 30, 2011	959,576	392,339	40.2	1,355.05
As of March 31, 2011	1,046,291	410,370	38.6	1,418.35

(Reference) Total equity less minority interests and stock options:
As of June 30, 2011 ¥386,142 million As of March 31, 2011 ¥404,170 million

2. Dividends

	Dividend per share				
	1Q end	2Q end	3Q end	Year-end	Total
	(¥)	(¥)	(¥)	(¥)	(¥)
Fiscal 2010	-	70.00	-	80.00	150.00
Fiscal 2011	-				
Fiscal 2011 (Forecast)		70.00	-	80.00	150.00

Note: Revisions to dividend forecast during the quarter: None

3. Consolidated Financial Forecasts for Fiscal 2011

(April 1, 2011 to March 31, 2012)

(Percentage figures show year-on-year change)

	Net sales		Operating income		Ordinary income		Net income		Basic earnings per share
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥)
First half	340,000	-17.5	50,000	-25.6	47,500	-23.6	31,500	-21.2	110.54
Full fiscal year	700,000	-9.0	109,000	-3.6	104,000	-1.1	69,500	3.1	243.90

Note: Revisions to financial forecasts during the quarter: None

4. Other

Changes in number of significant subsidiaries* in connection with changes to the scope of consolidation during the period : None

Increase: None Decrease: None

*Subsidiaries that meet the following criteria:

1. The subsidiary's sales or purchases from the parent company represent 10% or more of the sales or purchases of the parent company.
2. The subsidiary's net assets are equal to or more than 30% of the net assets of the parent company
3. The amount of common stock is equal to or more than 10% of that of the parent company

Application of special accounting treatment in preparation of consolidated quarterly financial statements: None

Changes in accounting policies, accounting estimate and restatement:

1) Changes in connection with the amendment of accounting standards: Yes
2) Changes other than (1): None
3) Change in accounting estimate: None
4) Restatement: None

Number of shares issued and outstanding (common stock):

1) Number of shares issued and outstanding as of the end of the reporting period (including treasury stock)

1Q Fiscal 2011: 296,566,949 shares Fiscal 2010: 296,566,949 shares

2) Number of shares of treasury stock as of the end of the reporting period:

1Q Fiscal 2011: 11,602,586 shares Fiscal 2010: 11,608,283 shares

3) Average number of outstanding shares (quarterly cumulative):

1Q Fiscal 2011: 284,960,537 shares 1QFiscal 2010: 284,936,904 shares

* Disclosure concerning the implementation status of quarterly review procedures:
This quarterly financial report is exempt from quarterly review procedures as stipulated under the Financial Instruments and Exchange Act of Japan. At the time of this quarterly financial report's disclosure, quarterly financial statement review procedures have not been completed as stipulated under the Financial Instruments and Exchange Act of Japan.

* Explanation concerning the appropriate use of results forecast and other special instructions:
Please refer to page 8 for details with regard to the assumptions and other related matters concerning consolidated financial results forecasts

Reference Materials

Table of Contents

(Page)

1. Qualitative Information Concerning Consolidated Financial Results

1) Qualitative Information Concerning Consolidated Operating Results

(April 1, 2011 to June 30, 2011)

[Sales and Income]

○ Eisai Co., Ltd. ("the Company") and its consolidated subsidiaries (collectively referred to as "the Group") recorded the following **consolidated financial results** for the quarter ended June 30, 2011:

Net sales:	¥167,292 million (down 18.2% year on year)
Operating income:	¥22,215 million (down 32.2% year on year)
Ordinary income:	¥21,158 million (down 29.9% year on year)
Net income:	¥13,505 million (down 28.1% year on year)

○ **Sales of Aricept**, an anti-Alzheimer's agent, declined to ¥42,010 million (down 49.3% year on year), as a result of the impact caused by the expiration of the composition of matter patent in the United States. **Sales of Pariet** (U.S. brand name: Aciphex), a proton pump inhibitor, came to ¥33,213 million (down 5.9% year on year). On the other hand, the Group is further expanding its oncology franchise towards the transformation strategy goal defined in the Group's mid-term strategic plan "HAYABUSA". **Sales of oncology related products** increased to ¥23,990 million (up 18.2% year on year). The ratio of sales of oncology related products to the Group's consolidated net sales expanded to 14.3% from the ratio of the first quarter of the previous fiscal year of 9.9%.

○ Selling expenses significantly declined as a result of lower alliance fees paid to Pfizer Inc. following the Aricept patent expiration in the United States. However, **operating income, ordinary income, and net income** decreased due to a decrease in gross income as a result of lower net sales, and the continued investment of resources in R&D activities.

○ As a result, **basic earnings per share** for the period came to ¥47.39 (down ¥18.55 per share from the same period of the previous fiscal year).

○ **Comprehensive income** for the period after adding/deducting minority interests and other comprehensive income to/from net income came to ¥4,739 million.

[Cash Income]

○ The Group uses **cash income** as a managerial index to express its ability to generate cash.

○ Cash income is the total amount of cash available for investment in future growth, dividend payments, repayment of borrowings, and other expenditures. The Group considers cash income as an indicator to assess corporate growth potential and strategies.

○ **Net income** was ¥13,505 million; **depreciation of property, plant and equipment** and **amortization of intangible assets** was ¥10,529 million; **amortization of goodwill** was ¥1,851 million.

○ As a result, **cash income** for this period was ¥25,885 million (down 20.6% year on year), with **cash income per share** of ¥90.84 (down ¥23.53 per share from the same period of the previous fiscal year).

*Cash income = Net income (loss) + depreciation of PP&E and amortization of intangible assets + in-process R&D expenses + amortization of goodwill + loss on impairment of long-lived assets (incl. loss on devaluation of investment securities)

*Cash income per share = Cash Income / average number of outstanding shares for the period (after deduction of treasury stock)

［Performance by Segment］

(Net sales for each segment include only sales to external customers.)

The Eisai Group's segments comprise the Pharmaceuticals and Other businesses, with the Pharmaceuticals business of each region being identified as a reporting segment.

Effective from the fiscal year ending March 31, 2012, the Group has designated four new reporting segments for its Pharmaceuticals Business: East Asia (Japan, China, Korea, Taiwan, and Hong Kong), the United States, Europe and New Markets & ASEAN (including Brazil, Russia, Canada, Australia, India, Middle East, and Southeast Asia). In line with this change, net sales figures listed in this report for each segment for the fiscal year ended March 31, 2011 are based on the new reporting segments.

＜East Asia Pharmaceuticals Business＞

○ **Net sales** totaled ¥98,840 million (up 5.8% year on year), with **segment profit** of ¥42,216 million (up 9.6% year on year). Of this amount, ¥91,774 million (up 6.5% year on year) was recorded by the Japan Pharmaceuticals Business, with **segment profit** of ¥40,308 million (up 9.5% year on year). **The ratio of net sales of the East Asia pharmaceutical business** to the total net sales of the Group increased 59.1% from 45.7% year on year, an increase of 13.4 percentage points from the first quarter of the previous fiscal year. The Group is steadily transforming to achieve the regional balance goal set forth in the mid-term strategic plan "HAYABUSA".

○ **Sales of Aricept** increased to ¥29,983 million (up 13.0% year on year), while **sales of Pariet** decreased to ¥15,508 million (down 3.2% year on year). Of this amount, ¥28,537 million (up 12.9% year on year) in **Aricept sales** and ¥14,783 million (down 2.1% year on year) **in Pariet sales** were recorded by the Japan Pharmaceuticals Business.

○ **Halaven,** a novel anticancer agent approved for the treatment of inoperable or recurrent breast cancer by the Japanese regulatory authority, was launched in Japan in July 2011.

＜United States Pharmaceuticals Business＞

○ **Net sales** totaled ¥44,764 million (down 49.4% year on year; down 43.1% on a U.S. dollar-denominated basis), with **segment profit** of ¥10,344 million (down 61.0% year on year, down 56.1% on a U.S. dollar-denominated basis).

○ **Sales of Aricept** came to ¥4,690 million (down 90.7% year on year; down 89.5% on a U.S. dollar-denominated basis), while **sales of Aciphex** came to ¥15,832 million (down 6.8% year on year; up 4.9% on a U.S. dollar-denominated basis). **Sales of Halaven** totaled ¥2,497 million.

○ Among the sales of Aricept in the U.S., **sales of Aricept 23 mg tablet**, a higher dose formulation of Aricept, during the period totaled ¥779 million, while sales of **Aricept AG** (Authorized Generic; generic products that are marketed under the agreement of the brand company) came to ¥2,433 million.

＜Europe Pharmaceuticals Business＞

○ **Net sales** totaled ¥12,261 million (up 10.3% year on year), with **segment profit** of ¥1,097 million (down 14.2% year on year).

○ **Sales of Aricept** came to ¥6,834 million (up 18.3% year on year), and **sales of Pariet** came to ¥1,447 million (down 20.3% year on year). Halaven was launched in Europe. **Sales of Halaven** totaled ¥98 million.

＜New Markets & ASEAN Pharmaceuticals Business＞

○ **Net sales** totaled ¥1,802 million (up 0.5% year on year), with **segment profit** of ¥155 million (down 53.5% year on year).

○ **Sales of Aricept** came to ¥502 million (up 12.9% year on year), and **sales of Pariet** came to ¥ 423 million (down 7.7% year on year).

○ **Halaven** was launched in Singapore in April 2011.

○ Anti-epileptic agent **Banzel** received approval in Canada. The Group also established a pharmaceutical sales subsidiary in Brazil in an effort to expand the business infrastructure in New Markets.

2) Research & Development Pipelines, Alliances, and Other Events

［Status of Ongoing Research & Development Pipelines］

○ The **anticancer agent Halaven** (“E7389”, microtubule dynamics inhibitor) received approval as a treatment of breast cancer in the U.S. and in other markets including Singapore, the European Union (EU), Japan and Switzerland. As of July 2011, the agent is approved in 34 countries worldwide. A Phase III study investigating the agent as a potential treatment for sarcoma is underway in the U.S. In addition, the Group is conducting clinical studies to develop the agent as a potential second-line treatment for breast cancer (Phase III in the U.S. and Europe) and for non-small cell lung cancer (Phase II in the U.S.).

○ The application submitted for the **AMPA-type glutamate receptor antagonist E2007** seeking approval to use the agent as an adjunctive therapy in epilepsy patients with partial seizures was accepted for review in Europe in June 2011. In the U.S., the Group submitted an application to the U.S. Food and Drug Administration (FDA) in May 2011. Upon preliminary review, the FDA has requested additional information including reformatting of some datasets. The Group is currently working to prepare for the resubmission. A Phase III study investigating the agent as a potential treatment for generalized seizures in patients with epilepsy is currently underway in the U.S., Europe and Japan and is being conducted as a global development program.

○ In May 2011, the **calcium channel blocking anti-arrhythmic agent Vasolan** Tablets 40 mg and Vasolan for Intravenous Injection 5 mg received approval in Japan for an additional indication as a treatment for pediatric patients with supraventricular tachyarrhythmia.

○ In June 2011, the **antiepileptic agent Banzel** received approval in Canada for use in the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in children 4 years and older and adults.

○ In July 2011, polyarticular juvenile idiopathic arthritis (JIA) was approved in Japan as an additional indication for the **fully human anti-TNF-α monoclonal antibody Humira**. In addition, Humira Pre-filled Syringe 20 mg/0.4 mL for Subcutaneous Injection, a new formulation for patients with a low body weight, also received approval.

○ In July 2011, a new granule formulation of the **oral anticoagulant Warfarin** received approval in Japan.

○ In July 2011, the supplemental New Drug Application (sNDA) submitted in the U.S. seeking approval of acute myeloid leukemia (AML) as an additional indication for the **DNA methylation inhibitor Dacogen** (decitabine) for injection was accepted for review by the U.S. Food and Drug Administration (FDA). A Phase II study investigating the agent as a potential treatment for AML in pediatric patients is currently underway in the U.S.

○ In July 2011, the application submitted in Europe seeking approval of an additional indication for the **antiepileptic agent Zonegran** for monotherapy in patients with partial seizures was accepted for review by the European Medicines Agency (EMA).

○ In July 2011, the application seeking approval of a pediatric indication for the **oral anticoagulant Warfarin granules** was submitted in Japan.

○ A Phase III study investigating the **anticancer agent E7080** (VEGF receptor tyrosine kinase /multi-kinase inhibitor) as a potential treatment for thyroid cancer was initiated in Japan following the study initiation in the U.S. This study is being conducted as a global development program. In addition, Phase II studies investigating the agent as a potential treatment for endometrial cancer (U.S. and Europe), melanoma (U.S. and Europe), and glioma (U.S.) are also ongoing.

○ A global Phase III study of the anticancer agent **MORAb-003** (monoclonal antibody) for platinum-sensitive ovarian cancer is ongoing. A Phase II/III study for platinum-resistant ovarian cancer was initiated and is now underway in the U.S. and Europe. A Phase II study for non-small cell lung cancer using folate receptor alpha as a biomarker is also ongoing in the U.S.

○ A Phase III study investigating **the anticancer agent Ontak** as a potential treatment for **peripheral T-cell lymphoma** was initiated and is ongoing in the U.S.

○ A Phase II/III study of the **proton pump inhibitor Pariet** for the prevention of recurrence of gastric/duodenal ulcers during treatment with low-dosage aspirin was initiated in Japan.

○ A Phase II study of the **anticancer agent MORAb-004 (monoclonal antibody)** for melanoma was initiated and is ongoing in the U.S.

［Status of Major Alliances and Agreements］

○ In April 2011, Eisai Co., Ltd. concluded a **license and collaborative research and development agreement with PRISM BioLab Corporation** (Yokohama) concerning a CBP/β-catenin inhibitor and analogous compounds thereof.

［Other Events］

○ In April 2011, EIDIA Co., Ltd. launched the **Cobas h 232 Series, a point-of-care testing system for use in the early diagnosis of cardiovascular emergencies.** Eisai Co. Ltd. is serving as co-promotion partner for the product.

○ In April 2011, the Eisai Group **established Eisai Participações Ltda. (Eisai Brazil)** in Brazil as its first pharmaceutical sales subsidiary in Latin America.

○ In April 2011, the **pancreatic enzyme replacement drug Lipacreon,** which was co-developed by Eisai Co., Ltd. and Solvay Seiyaku K.K. (currently Abbott Japan Co., Ltd.), received approval in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI). The product will be marketed by Eisai following NHI price registration.

○ In May 2011, the anticancer agent Symbenda (product name in Japan: Treakysim) received approval for the treatment of chronic lymphocytic leukemia and multiple myeloma from the regulatory authority in South Korea.

3) Qualitative Information Concerning Financial Position

［Assets, Liabilities and Equity］

○ **Total assets** as of the end of this period amounted to ¥959,576 million (down ¥86,714 million from the end of the previous fiscal year). This decrease in total assets is attributable to cash expenditures to redeem at maturity the Company's 5th series of unsecured straight bonds of ¥40,000 million issued in 2008, as well as decreases in assets of overseas subsidiaries as a result of yen appreciation.

○ **Total liabilities** as of the end of this period decreased to ¥567,237 million (down ¥68,683 million from the end of the previous fiscal year) as a result of such factors as the redemption of corporate bonds at maturity.

○ **Total equity** as of the end of this period decreased to ¥392,339 million (down ¥18,031 million from the end of the previous fiscal year) as a result of such factors such as dividend payment. The shareholders' equity ratio was 40.2% (up 1.6 percentage points from the end of the previous fiscal year).

［Cash Flow］(April 1, 2011 to June 30, 2011)

- ○ **Net cash provided by operating activities** for the quarter ended June 30, 2011 amounted to ¥7,807 million (down ¥20,371 million from the same period of the previous fiscal year). More specifically, **income before income taxes and minority interests** was ¥21,127 million; **depreciation and amortization** was ¥10,529 million; and **income taxes-paid** was ¥23,002 million.
- ○ **Net cash provided by investing activities** amounted to ¥28,217 million (¥5,069 million was used in the same period of the previous fiscal year). Of this amount, the net decrease in **time deposits exceeding three months** was ¥30,845 million.
- ○ **Net cash used in financing activities** amounted to ¥63,125 million (up ¥31,991 million from the same period of the previous fiscal year). Of this amount, ¥40,000 million was used for **redemption of corporate bonds at maturity,** while ¥22,796 million was used for **dividend payments**.
- ○ As a result, **cash and cash equivalents** as of the end of this period stood at ¥73,878 million (down ¥28,922 million from the end of the previous fiscal year).

4) Consolidated Financial Forecasts for Fiscal 2011

(April 1, 2011 to March 31, 2012)

[**Consolidated Forecasts]**

- Consolidated **forecasts** for the first half and full fiscal year **remain unchanged** from those announced in May 2011.

(Percentage figures show year-on-year change)

	Net sales		Operating income		Ordinary income		Net income		Basic earnings per share
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥)
First half	340,000	-17.5	50,000	-25.6	47,500	-23.6	31,500	-21.2	110.54
Full fiscal year	700,000	-9.0	109,000	-3.6	104,000	-1.1	69,500	3.1	243.90

(Assumptions: 1 USD=¥85, 1 EUR =¥110, 1 GBP =¥135)

Forecasts and Risk Factors

- Materials and information provided in this financial disclosure may contain “forward looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, and actual outcomes and results could differ materially from these statements. Risks and uncertainties include general industry and market conditions, as well as general domestic and international economic conditions such as interest rate and currency exchange fluctuations.
- Risks that could cause significant fluctuations in the consolidated results of the Eisai Group or have a material effect on investment decisions include: risks related to overseas operations; uncertainty of new drug development; risks related to dependence on specific products; risks in alliances with other companies; impact of measures to contain medical costs; competition and lawsuits with respect to generic products; risks related to intellectual property; risks of occurrences of side effects; risks regarding regulations; risks relating to lawsuits; plant closure/shutdown; risks concerning the safety and quality of raw materials; risks associated with outsourcing; environmental risks; risks concerning IT security and information management; risks related to financial markets and currency movement; and risks concerning internal control systems. These risks, however, have been evaluated and forecasted as of the disclosure date of this financial report.

For further details on the abovementioned risks, please refer to “Risk Factors” section of the Annual Securities Report

5) Corporate Governance

(1) Appointment of Directors

Eleven Directors, including seven Outside Directors, were appointed and assumed their respective offices effective June 21, 2011, the date of the 99th Ordinary General Meeting of Shareholders.

Outside Directors in particular must meet the requirements for Outside Directors set forth in Article 2-3-7 of the Ordinance for Enforcement of Japan's Companies Act, as well as satisfy the following Independence and Neutrality Requirements established by the Company's Nomination Committee.

Requirements for the Independence and Neutrality of Outside Directors

(Revised on January 30, 2009)

1. An Outside Director must be economically independent from Eisai Co., Ltd. or its affiliated companies (hereinafter referred to as the Eisai Group collectively) as well as from specified enterprises, etc., as demonstrated by satisfying the following conditions:
   - i) An Outside Director must not have received directly from the Eisai Group, in the past five years, compensation or remuneration for work or transactions (excluding director compensation from Eisai) at or above the fixed amount defined as follows:
     - a The "fixed amount" is defined as ¥10 million or more in any given fiscal year out of the past five years.
     - b Even when the individual has received the amount indirectly, the actual situation shall be judged prudently.
   - ii) An Outside Director must not have been, in the past five years, a Director, Executive Officer, or other officer of the any of the types of enterprises (including holding companies) defined as follows:
     - a Enterprises, etc., for which 2% or more of its sales in any given fiscal year out of the past five years have been sales or compensation for work or transactions with the Eisai Group;
     - b Regardless of the previous item, enterprises, etc., with a relationship of substantial interest with Eisai or its affiliated companies, such as Eisai's audit corporation;
     - c Enterprises, etc., that are major shareholders of the company (holding 10% or more of the company's outstanding shares); or
     - d Enterprises, etc., in which the Eisai Group is a major shareholder (holding 10% or more of the outstanding shares of the relevant enterprise, etc.)
   - iii) Even if an Outside Director has retired from their position as a Director, Executive Officer, or other officer of the types of enterprises specified above for the past five years, the Nomination Committee must determine that the Outside Director is independent and neutral with respect to these enterprises based on consideration of the following factors:
     - a The Outside Director's shareholding in the relevant enterprise, etc.
     - b The Outside Director's post-retirement remuneration from the relevant enterprise, etc.
     - c Human interaction between the Eisai Group and the relevant enterprise, etc.
2. An Outside Director must not be a close relative of, or one having a similar relationship to, a Director or Executive Officer of the Eisai Group.
   - i) A "close relative" is defined as a spouse, a blood relative within three degrees of kinship, or a cohabitating relative.
   - ii) "One having a similar relationship to" is defined as one having a human relationship that can be rationally recognized as that which makes it impossible for the individual to fulfill duties as an independent Director, such as a personally interested individual.
3. An Outside Director may not be of the same household as persons with any of the conflicts of interest described in paragraph 1.
4. In addition, there must not be any other situations rationally recognizable as preventing an Outside Director from performing duties as an independent Director.
5. The requirements for the independence and neutrality of Outside Directors defined in this article continue to apply after the appointment as Outside Director.

2) Structure of the Board of Directors and Executive Officers

At the Board of Directors meeting held following the closing of the 99th Ordinary General Meeting of Shareholders, the Chair of the Board of Directors, as well as Chairs and members of the Nomination, Audit and Compensation committees, were appointed and assumed their respective offices.
(*=denotes outside directors.)

Haruo Naito	President (Representative Executive Officer) and CEO
Junji Miyahara*	Nomination Committee Member, Compensation Committee Member
Kimitoshi Yabuki*	Audit Committee Member
Akira Fujiyoshi	Audit Committee Member
Christina Ahmadjian*	Audit Committee Member
Tokuji Izumi*	Chairman of the Board of Directors
Koichi Masuda*	Chair of the Audit Committee
Norio Kano	Audit Committee Member
Kiyochika Ota*	Chair of the Nomination Committee, Compensation Committee Member
Michikazu Aoi*	Chair of the Compensation Committee, Nomination Committee Member
Hideaki Matsui	

Independent Committee of Outside Directors comprises all outside directors.

3) Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders

At a meeting on June 21, 2011, the Independent Committee of Outside Directors (Chair: Kimitoshi Yabuki) resolved to propose that the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" (the "Policy") be continued in its present form as it incorporates the following provisions.

a) The Policy precludes arbitrary action on the part of management.

b) The continuation, amendment or abandonment of the Policy shall be deliberated each year.

c) Shareholders' opinions concerning the Policy may be reflected through the election of Directors at the Ordinary General Meeting of Shareholders.

In consideration of the fact that the Group finished its 5th Mid-term Strategic Plan one year earlier than scheduled in order to enact its new Mid-term Strategic Plan "HAYABUSA" from fiscal 2011, the Independent Committee of Outside Directors determined it appropriate to propose to the Board of Directors that the Policy remain in effect until June 30, 2016 to cover the entire period of the "HAYABUSA" Plan (April 2011 through March 2016), as well as to make necessary revisions to the Policy by adding additional clauses or amending wording to reflect revisions made to relevant laws and regulations and rules of Tokyo Stock Exchange since enactment of this Policy, and recent discussions regarding anti-takeover measures.

At the Board of Directors meeting held on August 2, 2011, a proposal by the Independent Committee of Outside Directors regarding the continuation of the Policy was deliberated and approved, with the Company announcing this resolution in a news release entitled “Policy for Protection of the Company’s Corporate Value and the Common Interests of Shareholders” on the same day

For further details on the Policy, please visit: http://www.eisai.co.jp/ecompany/egovernance.html

2 . Other Information

1) Changes in Number of Significant Subsidiaries During the Period

Not applicable

2) Application of Special Accounting Treatment in Preparation of Consolidated Quarterly Financial Statements

Not applicable

3) Changes in Accounting Policies, Accounting Estimates and Restatement

Effective from the first quarter of the fiscal year ending March 31, 2012, the “Accounting Standard for Earnings Per Share” (ASBJ Statement No. 2 released on June 30, 2010) and the “Guidance on Accounting Standard for Earnings Per Share” (ASBJ Guidance No. 4 released on June 30, 2010) have been adopted.

As a result, in calculating diluted earnings per share, for stock options which the right to exercise options is vested after a specified service period, the fair value of service expected to be provided to the Group in the future is added to the proceeds assumed to be received when options are exercised.

Diluted earnings per share for the first quarter of the fiscal year ended March 31, 2011 in cases where these accounting standards were not adopted was ¥65.94.

(Additional information)

In terms of changes in accounting policies and correction of errors contained in past reports after the beginning of the first quarter of the fiscal year ending Mach 31, 2012, the “Accounting Changes and Error Corrections” (ASBJ Statement No. 24 released on December 4, 2009) and the “Guidance on Accounting Changes and Error Corrections” (ASBJ Guidance No. 24 released on December 4, 2009) have been applied.

3. Consolidated Financial Statements

1) Consolidated Balance Sheets

(millions of yen)

	March 31, 2011	June 30, 2011
Assets		
Current assets		
Cash and cash in banks	111,356	68,881
Notes and accounts receivable-trade	195,234	195,022
Short-term investments	70,301	52,237
Merchandise and finished goods	38,496	39,561
Work in process	18,677	19,290
Raw materials and supplies	13,633	11,780
Deferred tax assets	39,172	39,595
Other	22,576	18,567
Allowance for doubtful receivables	(89)	(117)
Total current assets	509,359	444,818
Non-current assets		
Property, plant and equipment		
Buildings and structures-net	85,232	83,077
Other-net	63,900	62,052
Total property, plant and equipment	149,132	145,129
Intangible assets		
Goodwill	128,450	122,817
Sales rights	83,037	76,716
Core technology	43,687	41,755
Other	13,035	12,505
Total intangible assets	268,211	253,794
Investments and other assets		
Investment securities	54,561	53,283
Deferred tax assets	57,802	55,858
Other	7,428	6,898
Allowance for doubtful accounts	(204)	(206)
Total investments and other assets	119,588	115,834
Total non-current assets	536,932	514,758
Total assets	1,046,291	959,576

(millions of yen)

	March 31, 2011	June 30, 2011
Liabilities		
Current liabilities		
Notes and accounts payable-trade	22,004	23,446
Bonds and debentures (current portion)	39,999	-
Accounts payable-other	46,432	40,508
Accrued expenses	58,805	58,923
Income tax payable	24,070	6,051
Reserve for sales rebates	23,872	18,052
Other reserves	500	605
Other	9,430	10,520
Total current liabilities	225,116	158,109
Non-current liabilities		
Bonds and debentures	79,992	79,992
Long-term borrowings	259,890	258,438
Deferred tax liabilities	24,802	22,717
Liability for retirement benefits	29,225	31,382
Retirement allowances for directors	805	593
Other	16,089	16,004
Total non-current liabilities	410,804	409,128
Total liabilities	635,921	567,237
Equity		
Owners' equity		
Common stock	44,985	44,985
Capital surplus	56,910	56,905
Retained earnings	448,410	439,118
Treasury stock	(39,499)	(39,479)
Total owners' equity	510,807	501,530
Accumulated other comprehensive income		
Net unrealized gain (loss) on available-for-sale securities	69	(513)
Deferred gain (loss) on derivatives under hedge accounting	(808)	(949)
Foreign currency translation adjustments	(105,898)	(113,925)
Total accumulated other comprehenisve income	(106,636)	(115,388)
Stock options	870	900
Minority interests	5,329	5,295
Total equity	410,370	392,339
Total liabilities and equity	1,046,291	959,576

2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income (Consolidated Statements of Income)

(millions of yen)

	April 1, 2010- June 30, 2010	April 1, 2011- June 30, 2011
Net sales	204,463	167,292
Cost of sales	43,577	42,961
Gross profit	160,885	124,330
Provision for sales returns-net	-	40
Reversal of provision for sales returns-net	35	-
Gross profit-net	160,921	124,290
Selling, general and administrative expenses	128,148	102,074
Operating income	32,773	22,215
Non-operating income		
Interest income	215	206
Dividend income	519	529
Foreign exchange gain	-	22
Other	90	69
Total non-operating income	825	828
Non-operating expenses		
Interest expense	1,885	1,820
Foreign exchange loss	1,453	-
Other	92	64
Total non-operating expenses	3,431	1,884
Ordinary income	30,167	21,158
Special gains		
Gain on sales of fixed assets	27	1
Other	19	-
Total special gains	46	1
Special losses		
Loss on disposal of fixed assets	48	28
Loss on devaluation of investment securities	321	-
Effect of adoption of Accounting Standard for Asset Retirement Obligations	654	-
Other	2	3
Total special losses	1,028	32
Income before income taxes and minority interests	29,185	21,127
Income taxes-current	12,490	6,487
Income taxes-deferred	(2,203)	1,034
Total income taxes	10,287	7,522
Income before minority interests	18,898	13,605
Minority interests in income	109	100
Net income	18,789	13,505

(Consolidated Statements of Comprehensive Income)

(millions of yen)

	April 1, 2010- June 30, 2010	April 1, 2011- June 30, 2011
Income before minority interests	18,898	13,605
Other comprehensive income		
Net unrealized gain (loss) on available-for-sale securities	(1,281)	(589)
Deferred gain (loss) on derivatives under hedge accounting	(455)	(141)
Foreign currency translation adjustments	(17,985)	(8,135)
Total other comprehensive income	(19,722)	(8,865)
Comprehensive Income	(823)	4,739
(Breakdown)		
Comprehensive income attributable to shareholders of the parent company	(812)	4,753
Comprehensive income attributable to minority interests	(11)	(13)

3) Consolidated Statements of Cash Flows

(millions of yen)

	April 1, 2010 - June 30, 2010	April 1, 2011 - June 30, 2011
Operating activities		
Income before income taxes and minority interests	29,185	21,127
Depreciation and amortization	11,384	10,529
Amortization of goodwill	2,093	1,851
Other loss (gain)-net	1,490	1,118
Decrease (increase) in notes and accounts receivable-trade	(11,415)	(1,048)
Decrease (increase) in inventories	(1,100)	(619)
Increase (decrease) in trade payables	4,481	1,777
Increase (decrease) in other current liabilities	(2,366)	(2,703)
Increase (decrease) in reserve for sales rebates	2,208	(5,190)
Other-net	(719)	4,895
Sub-total	35,243	31,737
Interest and dividends received	727	746
Interest paid	(1,712)	(1,673)
Income taxes paid	(6,079)	(23,002)
Net cash provided by (used in) operating activities	28,178	7,807
Investing activities		
Purchases of property, plant and equipment	(3,345)	(3,095)
Purchases of intangible assets	(1,038)	(538)
Purchases of investment securities	(657)	(1,524)
Proceeds from sales and redemptions of investment securities	803	2,355
Net decrease (increase) in time deposit exceeding three months	(901)	30,845
Other-net	70	176
Net cash provided by (used in) investing activities	(5,069)	28,217
Financing activities		
Net increase (decrease) in short-term borrowings	(8,000)	-
Redemption of bonds and debentures	-	(40,000)
Dividends paid	(22,795)	(22,796)
Other-net	(339)	(329)
Net cash provided by (used in) financing activities	(31,134)	(63,125)
Foreign currency translation adjustments on cash and cash equivalents	(5,661)	(1,821)
Net increase (decrease) in cash and cash equivalents	(13,687)	(28,922)
Cash and cash equivalents at beginning of the fiscal year	115,128	102,800
Cash and cash equivalents at end of the quarter	101,441	73,878

4) Going Concern

Not applicable

5) Segment Information

Effective from the first quarter of the fiscal year ending March 31, 2012, the Eisai Group has reorganized its reporting segments.

I. First quarter of the fiscal year ended March 31, 2011 (April 1, 2010 to June 30, 2010)

Information concerning sales and profit (loss) for the first quarter of the fiscal year ended March 2011 based on the new reporting segments is as follows.

(1) Information concerning sales and profit (loss) by reporting segment

(millions of yen)

	Reporting Segment					Other (Note)	Total
	Pharmaceuticals Business						
	East Asia	United States	Europe	New Markets & ASEAN	Sub-total		
Sales to external customers	93,401	88,554	11,119	1,793	194,868	9,595	204,463
Segment profit	38,501	26,512	1,278	335	66,628	4,076	70,704

Note: "Other" is a business segment not included in reporting segments. Pharmaceutical raw materials and machinery businesses are included in this segment.

(2) Amounts and main components of difference between reporting segment total and consolidated statements of income (items concerning difference adjustment)

(millions of yen)

Profit Item	Amount
Reporting segment total	66,628
Profit included in "Other"	4,076
R&D expenses[1]	(36,028)
Group headquarters management costs and other expenses[2]	(1,903)
Operating income as reported in the consolidated financial statements	32,773

(Note) 1 R&D expenses are not allocated to any particular segment as the Group manages such expense on a global basis.

2 Group headquarters management costs and other expenses are not allocated to any particular segment as this is the cost covering Group-wide operations.

(3) Information concerning loss on impairment of long-lived assets and goodwill by reporting segment

Not applicable

II. First quarter of the fiscal year ending March 31, 2012 (April 1, 2011 to June 30, 2011)

(1) Information concerning sales and profit (loss) by reporting segment

(millions of yen)

	Reporting Segment					Other (Note)	Total
	Pharmaceuticals Business						
	East Asia	United States	Europe	New Markets & ASEAN	Sub-total		
Sales to external customers	98,840	44,764	12,261	1,802	157,669	9,623	167,292
Segment profit	42,216	10,344	1,097	155	53,814	4,447	58,262

Note: "Other" is a business segment not included in reporting segments. Pharmaceutical raw materials and machinery businesses are included in this segment.

(2) Amounts and main components of difference between reporting segment total and consolidated statements of income (items concerning difference adjustment)

(millions of yen)

Profit Item	Amount
Reporting segment total	53,814
Profit included in "Other"	4,447
R&D expenses[1]	(33,721)
Group headquarters management costs and other expenses[2]	(2,325)
Operating income as reported in the consolidated financial statements	22,215

(Note) 1 R&D expenses are not allocated to any particular segment as the Group manages such expense on a global basis.
2 Group headquarters management costs and other expenses are not allocated to any particular segment as this is the cost covering Group-wide operations.

(3) Information concerning changes to reporting segments, etc.

The Eisai Group's segments comprise the Pharmaceuticals and Other businesses, with the Pharmaceuticals business of each region being identified as a reporting segment.

Previously, the Group's Pharmaceuticals Business comprised five regions: Japan, the United States, Europe, Asia (including China) and New Markets (India, Middle East, etc.), but effective from the first quarter of the fiscal year ending March 31, 2012, the business has been reorganized into four regions: East Asia, the United States, Europe and New Markets & ASEAN (including Brazil, Russia, Canada, Australia, India, Middle East, Southeast Asia).

As a result of these changes to reporting segments, the Japan Pharmaceuticals Business, as well as China, Korea, Taiwan, and Hong Kong which were previously included in the Asia Pharmaceuticals Business are now defined as the East Asia Pharmaceuticals Business, while the Asia Pharmaceuticals Business excluding China, Korea, Taiwan, and Hong Kong and the New Markets Pharmaceuticals Business are defined as New Markets & ASEAN Pharmaceuticals Business.

(4) Information concerning loss on impairment of long-lived assets and goodwill by reporting segment

Not applicable

6) Notes to Statements of Changes in Equity

Not applicable

7) Significant Subsequent Events

Not applicable

Securities Code: 4523

2011.6

Reference Data

First Quarter Ended June 30, 2011

August 2, 2011

For Inquiry:

Eisai Co., Ltd.

Public Relations / Investor Relations

TEL 81-3-3817-5120 FAX 81-3-3811-3077

http://www.eisai.co.jp/eir/

Forward-looking Statements and Risk Factors

Materials and information provided in this financial disclosure may contain “forward-looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions, such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on decisions of shareholders are described as follows. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to strategic alliances with partners, healthcare cost-containment measures, intensified competition with generic drugs, intellectual property, possible incidence of adverse events, compliance with laws and regulations, litigation, closure or shutdown of factories, safety/quality issues related to raw materials used, outsourcing-related risks, environmental issues, IT security/information management, and conditions of financial markets, foreign exchange fluctuations, internal control systems and disasters.

Contents

* All amounts are rounded to the nearest specified unit.
* The exchange rates used in the reference data are noted in the table below.
* All overseas profit and loss amounts have been converted into yen based on the average exchange rates for the periods shown in the table below.

Currency Exchange Rates

	US (¥/USD)	EU (¥/EUR)	UK (¥/GBP)	China (¥/RMB)
(Apr. 2010 - Jun. 2010) Three Months Average Rate	92.00	116.99	136.98	13.48
(Jun. 30, 2010) First Quarter End Rate	88.48	107.81	133.07	13.03
(Apr. 2010 - Mar. 2011) Fiscal Year Average Rate	85.72	113.12	133.13	12.76
(Mar. 31, 2011) Fiscal Year End Rate	83.15	117.57	133.89	12.68
(Apr. 2011 - Jun. 2011) Three Months Average Rate	81.74	117.40	133.23	12.56
(Jun. 30, 2011) First Quarter End Rate	80.73	116.84	129.78	12.47
Fiscal Year Ending March 31, 2012 Forecast Rate	85.00	110.00	135.00	12.50

About Indicators in this Reference Data

Eisai believes that cash generating ability is the most intrinsic element determining the true value of a company. Based upon this belief, in order to reflect our true earnings capacity, we focus on disclosing “cash income” and “cash EPS,” which are affected by non-cash profit-and-loss items, such as depreciation of property, plant and equipment, amortization of goodwill, loss on impairment of long-lived assets (including loss on devaluation of investment securities), and in-process R&D expenses.

Cash income

Cash income is the total amount of cash available for investment in future growth, dividend payments, repayment of borrowings, and other expenditures. We consider cash income as an indicator to assess corporate growth potential and strategies.

Cash income = Net income + Depreciation of PP&E and amortization of intangible assets + In-process R&D expenses + Amortization of goodwill + Loss on impairment of long-lived assets (including loss on devaluation of investment securities)

Cash income per share (Cash EPS)

Cash EPS = Cash income / Number of shares outstanding at the end of the period after deduction of treasury stock

Segment information

The Eisai Group’s segments comprise the Pharmaceuticals and Other businesses, with the Pharmaceuticals business of each region being identified as a reporting segment. Effective from the fiscal year ending March 31, 2012, the Group has designated four new reporting segments for its Pharmaceuticals Business: East Asia (Japan, China, Korea, Taiwan, and Hong Kong), the United States, Europe and New Markets & ASEAN (including Brazil, Russia, Canada, Australia, India, Middle East, and Southeast Asia). In line with this change, figures listed in this report for each segment for the fiscal year ended March 31, 2011 are based on the new reporting segments.

1. Consolidated Financial Highlights

1) Income Statement Data

(billions of yen)

	Three months ended June 30			Full Year	
	FY2010	FY2011	YOY %	FY2010	FY2011 est.
Net sales	204.5	167.3	81.8	768.9	700.0
Cost of sales	43.5	43.0	98.8	167.8	180.0
R&D expenses	36.0	33.7	93.6	145.0	132.0
SG&A expenses	92.1	68.4	74.2	343.0	279.0
Operating income	32.8	22.2	67.8	113.1	109.0
Ordinary income	30.2	21.2	70.1	105.2	104.0
Net income	18.8	13.5	71.9	67.4	69.5
Cash income	32.6	25.9	79.4	120.0	120.0
Comprehensive Income	(0.8)	4.7	-	31.2	-
			Diff.		
Dividend per share (DPS, yen)	-	-	-	150.0	150.0
Earnings per share (EPS, yen)	65.9	47.4	(18.5)	236.5	243.9
Cash income per share (Cash EPS, yen)	114.4	90.8	(23.5)	421.3	421.1

* "Cost of sales" includes "Provision for (reversal of) sales returns-net."

2) Cash Flow Statement Data

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	Diff.	FY2010
Net cash provided by operating activities	28.2	7.8	(20.4)	123.2
Net cash used in investing activities	(5.1)	28.2	33.3	(58.8)
Net cash provided by (used in) financing activities	(31.1)	(63.1)	(32.0)	(68.0)
Cash and cash equivalents at end of period	101.4	73.9	(27.6)	102.8
Free cash flow	23.9	4.2	(19.7)	100.3

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and other expenditures)"

3) Balance Sheet Data

(billions of yen)

	2011		Diff.
	March 31	June 30	
Total assets	1,046.3	959.6	(86.7)
Liabilities	635.9	567.2	(68.7)
Bonds and debentures	120.0	80.0	(40.0)
Borrowings	259.9	258.4	(1.5)
Equity	410.4	392.3	(18.0)
Shareholders' equity	404.2	386.1	(18.0)
Shareholders' equity ratio to total assets (%)	38.6	40.2	1.6
Liabilities ratio（Net DER/times)	0.49	0.56	0.07

* "Liabilities ratio（Net DER)" = ("Interest-bearing debt" ("Borrowings" + "Bonds and debentures") - "Cash and cash in banks" - "Short-term investments") / "Shareholders' equity"

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	Diff.	FY2010
Capital expenditures	3.5	2.7	(0.8)	23.7
Property, plant and equipment	2.5	1.8	(0.6)	14.4
Intangible assets	1.0	0.9	(0.2)	9.3
Depreciation and amortization	11.4	10.5	(0.9)	43.5

* "Depreciation and amortization" includes amortization of "Intangible assets."

5) Financial Results by Business Segment

(1) Consolidated Net Sales by Reporting Segment

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	YOY %	FY2010
East Asia pharmaceuticals business	93.4	98.8	105.8	375.7
Japan pharmaceuticals business	86.2	91.8	106.5	350.4
U.S. pharmaceuticals business	88.6	44.8	50.6	303.0
Europe pharmaceuticals business	11.1	12.3	110.3	44.4
New Markets & ASEAN pharmaceuticals business	1.8	1.8	100.5	6.9
Other	9.6	9.6	100.3	38.9
Consolidated net sales	204.5	167.3	81.8	768.9

* Net sales to external customers for each segment.

(2) Consolidated Operating Income by Reporting Segment

(billions of yen)

	Three months ended June 30		
	FY2010	FY2011	YOY %
East Asia pharmaceuticals business	38.5	42.2	109.6
Japan pharmaceuticals business	36.8	40.3	109.5
U.S. pharmaceuticals business	26.5	10.3	39.0
Europe pharmaceuticals business	1.3	1.1	85.8
New Markets & ASEAN pharmaceuticals business	0.3	0.2	46.5
Other	4.1	4.4	109.1
R&D expenses	36.0	33.7	93.6
Non-allocated SG&A expenses	1.9	2.3	122.2
Operating income	32.8	22.2	67.8

*The Group's Pharmaceuticals business is classified into segments comprising East Asia (Japan, China, Korea, Taiwan, and Hong Kong), the United States, Europe, and New Markets & ASEAN (Brazil, Russia, Canada, Australia, India, Middle East, East Asia, etc).
Steps are taken to pursue strategies and plans that take into account the specific characteristics and attributes of each region or market.
In the Pharmaceuticals business, the Group is mainly engaged in the manufacture and sale of prescription drugs.
The Group's segments comprise the Pharmaceuticals business and Other business, with the Pharmaceuticals business of each region being identified as a reporting segment.

2. Consolidated Statements of Income

(billions of yen)

	Three months ended June 30						Full Year	
	FY2010	Sales %	FY2011	Sales %	YOY %	Diff.	FY2010	Sales %
Net sales	204.5	100.0	167.3	100.0	81.8	(37.2)	768.9	100.0
Cost of sales	43.5	21.3	43.0	25.7	98.8	(0.5)	167.8	21.8
Gross profit	160.9	78.7	124.3	74.3	77.2	(36.6)	601.1	78.2
R&D expenses	36.0	17.6	33.7	20.2	93.6	(2.3)	145.0	18.9
SG&A expenses	92.1	45.1	68.4	40.9	74.2	(23.8)	343.0	44.6
Personnel expenses	20.5	10.0	20.7	12.4	101.0	0.2	84.2	10.9
Marketing and promotion expenses	57.3	28.0	34.6	20.7	60.4	(22.7)	202.6	26.3
Administrative and other expenses	14.3	7.0	13.0	7.8	90.9	(1.3)	56.3	7.3
Operating income	32.8	16.0	22.2	13.3	67.8	(10.6)	113.1	14.7
Non-operating income	0.8	0.4	0.8	0.5		0.0	2.2	0.3
Non-operating expense	3.4	1.7	1.9	1.1		(1.5)	10.1	1.3
Ordinary income	30.2	14.8	21.2	12.6	70.1	(9.0)	105.2	13.7
Special gain	0.0	0.0	0.0	0.0		(0.0)	0.3	0.0
Special loss	1.0	0.5	0.0	0.0		(1.0)	2.9	0.4
Income before income taxes and minority interests	29.2	14.3	21.1	12.6	72.4	(8.1)	102.6	13.3
Income taxes-current	12.5	6.1	6.5	3.9		(6.0)	37.2	4.8
Income taxes-deferred	(2.2)	(1.1)	1.0	0.6		3.2	(2.4)	(0.3)
Income before minority interests	18.9	9.2	13.6	8.1	72.0	(5.3)	67.8	8.8
Minority interests in net income	0.1	0.1	0.1	0.1		(0.0)	0.4	0.1
Net income	18.8	9.2	13.5	8.1	71.9	(5.3)	67.4	8.8

* "Cost of Sales" includes "Provision for (reversal of) sales returns-net."

Cash income

Net income	18.8	9.2	13.5	8.1	71.9	(5.3)	67.4	8.8
Depreciation of PP&E and amortization of intangible assets	6.7		6.4				26.1	
Amortization of intangible assets obtained by acquisition	4.7		4.1				17.4	
Amortization of goodwill	2.1		1.9				7.8	
Loss on impairment of long-lived assets (including loss on devaluation of investment securities)	0.3		-				1.4	
Cash income	32.6	15.9	25.9	15.5	79.4	(6.7)	120.0	15.6

Notes

Net sales	Decrease in sales of Aricept [- ¥40.9 billion] Increase in sales of oncology related products [+¥3.7 billion, 14.3% of consolidated net sales] Increase in share of net sales recorded by the East Asia pharmaceuticals business [+13.4%]
Cost of sales to net sales <Reason for increase>	Primarily due to change in U.S. product mix
R&D expenses <Reason for decrease>	Impact of currency exhange rate and other factors
SG&A expenses <Reason for decrease>	Decrease in alliance cost of Aricept in the U.S. Increased efficiency of SG&A expenses
Non-operating income/expense	Reversal of foreign exhange loss

Consolidated Statements of Comprehensive Income (billions of yen)

	Three months ended June 30				Full Year
	FY2010	FY2011	YOY %	Diff.	FY2010
Income before minority interests	18.9	13.6	72.0	(5.3)	67.8
Other comprehensive income	(19.7)	(8.9)	-	10.9	(36.6)
Net unrealized gain (loss) on available-for-sale securities	(1.3)	(0.6)		0.7	(4.8)
Deferred gain (loss) on derivatives under hedge accounting	(0.5)	(0.1)		0.3	(0.2)
Foreign currency translation adjustments	(18.0)	(8.1)		9.8	(31.6)
Comprehensive Income	(0.8)	4.7	-	5.6	31.2
(Breakdown)					
Comprehensive income attributable to shareholders of the parent company	(0.8)	4.8	-	5.6	30.9
Comprehensive income attributable to minority interests	(0.0)	(0.0)	-	(0.0)	0.3

*FY2010 amounts for the three months ended June 30 and indices that compare data with the same period of the previous fiscal year in consolidated statements of comprehensive income are provided for reference purposes only.

3. Consolidated Statements of Cash Flows

(billions of yen)

	Three months ended June 30		
	FY2010	FY2011	Diff.
Income before income taxes and minority interests	29.2	21.1	(8.1)
Depreciation and amortization	11.4	10.5	(0.9)
Decrease (increase) in notes and accounts receivable, trade payables and inventories	(8.0)	0.1	8.1
Increase (decrease) in accounts payable-other/accrued expenses, etc.	(2.4)	(2.7)	(0.3)
Other	5.1	2.7	(2.4)
[Sub-total]	35.2	31.7	(3.5)
Interest received (paid), etc.	(1.0)	(0.9)	0.1
Income taxes paid	(6.1)	(23.0)	(16.9)
Net cash provided by (used in) operating activities	28.2	7.8	(20.4)
Capital expenditures (incl. acquisition and other expenditures)	(4.3)	(3.6)	0.7
Proceeds from sales of (purchases of) securities	0.1	0.8	0.7
Net increase (decrease) in time deposits exceeding three months	(0.9)	30.8	31.7
Other	0.0	0.2	0.2
Net cash provided by (used in) investing activities	(5.1)	28.2	33.3
Net increase (decrease) in short-term borrowings	(8.0)	-	8.0
Redemption of corporate bonds	-	(40.0)	(40.0)
Dividends paid	(22.8)	(22.8)	(0.0)
Other-net	(0.3)	(0.3)	0.0
Net cash provided by (used in) financing activities	(31.1)	(63.1)	(32.0)
Foreign currency translation adjustments on cash and cash equivalents	(5.7)	(1.8)	3.8
Net increase (decrease) in cash and cash equivalents	(13.7)	(28.9)	(15.2)
Cash and cash equivalents at the beginning of period	115.1	102.8	(12.3)
Cash and cash equivalents at the end of period	101.4	73.9	(27.6)
Free cash flow	23.9	4.2	(19.7)

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and other expenditures)"

Notes

Net cash provided by (used in) operating activities <Reason for decrease>
Increase in income taxes paid due to an increase in taxable income in the previous year

Net cash provided by (used in) investing activities <Reason for increase>
Decrease in time deposits exceeding three months due to redemption of corporate bonds at maturity

Net cash provided by (used in) financing activities <Reason for increase>
Increase in expenditure due to redemption of corporate bonds at maturity and payment of cash dividends, etc.

4. Financial Results by Business Segment

1) East Asia Pharmaceuticals Business

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	YOY %	FY2010
Net sales	93.4	98.8	105.8 <106.3>	375.7
Segment profit	38.5	42.2	109.6	

East Asia Net Sales Breakdown

Net sales in Japan	86.2	91.8	106.5	350.4
Prescription drugs	77.1	82.1	106.4	311.1
Consumer health care products, etc.	4.5	5.0	111.0	20.7
Generic drugs (Elmed Eisai Co., Ltd.)	3.0	3.2	105.8	12.4
Diagnostic products (EIDIA Co., Ltd.)	1.5	1.5	99.6	6.1
Japan prescription drugs (Eisai)				
Anti-Alzheimer's agent Aricept	25.3	28.5	112.9	105.5
Proton pump inhibitor Pariet	15.1	14.8	97.9	60.2
Peripheral neuropathy treatment Methycobal	8.0	7.4	93.5	30.4
Fully human anti-TNF-alpha monoclonal antibody Humira	2.6	4.6	175.1	13.3
Osteoporosis treatment Actonel	2.9	2.9	99.2	11.5
Gastritis/gastric ulcer treatment Selbex	3.1	2.6	84.0	11.4
Oral anticoagulant Warfarin	2.4	2.4	100.0	9.6
Japan consumer health care major product groups (Eisai)				
Vitamin B_2 preparation Chocola BB Group	2.4	2.8	116.1	9.9

* Net sales of prescription drugs for the 1Q of FY2011 includes Lyrica co-promotion income of ¥2.1 billion.

Net sales in China	Billions JPY	4.2	4.1	97.5 <104.7>	14.1
China prescription drugs					
Peripheral neuropathy treatment Methycobal	Billions JPY [Millions RMB]	2.0 [149]	1.8 [146]	91.7 <98.4>	6.0 [474]
Liver Disease/Allergic Disease Agents Stronger Neo-Minophagen C and Glycyron Tablets	Billions JPY [Millions RMB]	0.8 [61]	0.8 [67]	102.4 <109.9>	3.0 [234]
Anti-Alzheimer's agent Aricept	Billions JPY [Millions RMB]	0.3 [22]	0.4 [31]	128.5 <137.9>	1.3 [99]
Proton pump inhibitor Pariet	Billions JPY [Millions RMB]	0.4 [26]	0.3 [20]	71.5 <76.7>	1.1 [86]

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

2) U.S. Pharmaceuticals Business

		Three months ended June 30		
		FY2010	FY2011	YOY %
Net sales	Billions JPY	88.6	44.8	50.6 <56.9>
Segment profit	Billions JPY	26.5	10.3	39.0
U.S. prescription drugs				
Proton pump inhibitor Aciphex	Billions JPY [Millions USD]	17.0 [185]	15.8 [194]	93.2 <104.9>
Antiemetic agent Aloxi	Billions JPY [Millions USD]	8.8 [96]	9.7 [118]	109.1 <122.8>
DNA hypomethylating agent Dacogen	Billions JPY [Millions USD]	4.3 [47]	4.9 [60]	113.1 <127.3>
Anti-Alzheimer's agent Aricept	Billions JPY [Millions USD]	50.2 [545]	4.7 [57]	9.3 <10.5>
Injectable anticoagulant Fragmin	Billions JPY [Millions USD]	4.3 [47]	3.5 [43]	81.4 <91.7>
Anticancer agent Halaven	Billions JPY [Millions USD]	-	2.5 [31]	-

*Sales of Aricept 23mg out of total sales of Aricept for the 1Q of FY2011 totaled ¥0.8 billion (US$10 million), while sales of AG (Authorized Generic: a generic product sold under license from the manufacturer of an original drug) totaled ¥2.4 billion (US$30 million).

3) Europe Pharmaceuticals Business

		Three months ended June 30		
		FY2010	FY2011	YOY %
Net sales	Billions JPY	11.1	12.3	110.3 <110.2>
Segment profit	Billions JPY	1.3	1.1	85.8
Europe prescription drugs				
Anti-Alzheimer's agent Aricept	Billions JPY	5.8	6.8	118.3 <118.6>
Proton pump inhibitor Pariet	Billions JPY	1.8	1.4	79.7 <79.5>
Anti-epileptic agent Zonegran	Billions JPY	1.1	1.2	109.3 <109.0>
Anticancer agent Halaven	Billions JPY	-	0.1	-

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

4) New Markets & ASEAN Pharmaceuticals Business

		Three months ended June 30		
		FY2010	FY2011	YOY %
Net sales	Billions JPY	1.8	1.8	100.5 <106.1>
Segment profit (loss)	Billions JPY	0.3	0.2	46.5
New Markets & ASEAN prescription drugs				
Anti-Alzheimer's agent Aricept	Billions JPY	0.4	0.5	112.9 <119.0>
Proton pump inhibitor Pariet	Billions JPY	0.5	0.4	92.3 <97.9>
Peripheral neuropathy treatment Methycobal	Billions JPY	0.3	0.3	91.6 <94.9>

*Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

5) Sales of Major Products

(1) Aricept (Anti-Alzheimer's agent)

		Three months ended June 30			Full Year
		FY2010	FY2011	YOY %	FY2010
Total	Billions JPY	82.9	42.0	50.7 <51.5>	290.4
Esat Asia	Billions JPY	26.5	30.0	113.0 <113.3>	110.8
Japan	Billions JPY	25.3	28.5	112.9	105.5
U.S.	Billions JPY	50.2	4.7	9.3	153.4
	[Millions USD]	[545]	[57]	<10.5>	[1,790]
Europe	Billions JPY	5.8	6.8	118.3 <118.6>	24.4
New Markets & ASEAN	Billions JPY	0.4	0.5	112.9 <119.0>	1.8

*Sales of Aricept 23mg out of total sales of Aricept for the 1Q of FY2011 totaled ¥0.8 billion (US$10 million), while sales of AG (Authorized Generic: a generic product sold under license from the manufacturer of an original drug) totaled ¥2.4 billion (US$30 million).

(2) Aciphex/Pariet (Proton pump inhibitor)

		Three months ended June 30			Full Year
		FY2010	FY2011	YOY %	FY2010
Total	Billions JPY	35.3	33.2	94.1 <99.9>	136.9
East Asia	Billions JPY	16.0	15.5	96.8 <97.0>	63.2
Japan	Billions JPY	15.1	14.8	97.9	60.2
U.S.	Billions JPY	17.0	15.8	93.2	65.6
	[Millions USD]	[185]	[194]	<104.9>	[765]
Europe	Billions JPY	1.8	1.4	79.7 <79.5>	6.4
New Markets & ASEAN	Billions JPY	0.5	0.4	92.3 <97.9>	1.8

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

(3) Oncology Related Products

		Three months ended June 30			Full Year
		FY2010	FY2011	YOY %	FY2010
Total	Billions JPY	20.3	24.0	118.2 <132.1>	80.3
Halaven (Anticancer agent)	Billions JPY	-	2.6	-	2.2
U.S.	Billions JPY [Millions USD]	-	2.5 [31]	-	2.2 [25]
Europe	Billions JPY	-	0.1	-	-
New Markets & ASEAN	Billions JPY	-	0.0	-	-
Aloxi (Antiemetic agent)					
U.S.	Billions JPY [Millions USD]	8.8 [96]	9.7 [118]	109.1 <122.8>	34.6 [403]
Dacogen (DNA hypomethylating agent)					
U.S.	Billions JPY [Millions USD]	4.3 [47]	4.9 [60]	113.1 <127.3>	16.2 [189]
Fragmin (Injectable anticoagulant)					
U.S.	Billions JPY [Millions USD]	4.3 [47]	3.5 [43]	81.4 <91.7>	16.4 [191]
Other*	Billions JPY	2.8	3.3	118.4	11.0

*Sales of "Other" for the 1Q of FY2011 includes sales of TREAKISYM/Symbenda, which totaled ¥0.8 billion.

(4) Humira (Fully human anti-TNF-alpha monoclonal antibody)

		Three months ended June 30			Full Year
		FY2010	FY2011	YOY %	FY2010
Total	Billions JPY	3.5	5.5	156.7 <157.5>	16.6
Japan	Billions JPY	2.6	4.6	175.1	13.3

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

6) Overseas Sales

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	YOY %	FY2010
Overseas sales	114.2	72.0	63.0	401.4
Overseas sales (% of total sales)	55.9	43.0	-	52.2

* Net sales to external customers for each segment.

5. Sales Forecast by Reporting Segment (FY2011)

(billions of yen)

	Three months ended June 30	Full Year	
	FY2011	FY2010	FY2011 est.
East Asia	98.8	375.7	408.0
Japan	91.8	350.4	380.5
Prescription drugs	82.1	311.1	338.0
Anti-Alzheimer's agent Aricept	28.5	105.5	114.0
Proton pump inhibitor Pariet	14.8	60.2	62.0
Peripheral neuropathy treatment Methycobal	7.4	30.4	30.0
Fully human anti-TNF-alpha monoclonal antibody Humira	4.6	13.3	22.0
Osteoporosis treatment Actonel	2.9	11.5	12.5
Gastritis/gastric ulcer treatment Selbex	2.6	11.4	10.5
Oral anticoagulant Warfarin	2.4	9.6	10.0
Consumer health care products, etc.	5.0	20.7	22.0
Vitamin B_2 preparation Chocola BB Group	2.8	9.9	11.0
Generic drugs (Elmed Eisai Co., Ltd.)	3.2	12.4	14.0
Diagnostic products (EIDIA Co., Ltd.)	1.5	6.1	6.5
China	4.1	14.1	16.0
U.S.	44.8	303.0	195.5
Europe	12.3	44.4	50.0
New Markets & ASEAN	1.8	6.9	8.5
Other	9.6	38.9	38.0
Consolidated net sales	167.3	768.9	700.0

* Sales forecast for Aricept for FY2011 is ¥187.5 billion.

* Sales forecast for Pariet/Aciphex for FY2011 is ¥132.5 billion.

* Sales forecast for Halaven for FY2011 is ¥18.5 billion.

6. Consolidated Balance Sheets

1) Consolidated Balance Sheets <Assets>

(billions of yen)

	March 31, 2011	%	June 30, 2011	%	YOY %	Diff.
Cash and cash in banks	111.4		68.9			(42.5)
Notes and accounts receivable-trade	195.2		195.0			(0.2)
Short-term investments	70.3		52.2			(18.1)
Inventories	70.8		70.6			(0.2)
Deferred tax assets	39.2		39.6			0.4
Other	22.6		18.6			(4.0)
Allowance for doubtful receivables	(0.1)		(0.1)			(0.0)
Total current assets	509.4	48.7	444.8	46.4	87.3	(64.5)
Buildings and structures-net	85.2		83.1			(2.2)
Other	63.9		62.1			(1.8)
Total property, plant and equipment-net	149.1	14.3	145.1	15.1	97.3	(4.0)
Goodwill	128.5		122.8			(5.6)
Sales rights	83.0		76.7			(6.3)
Core technology	43.7		41.8			(1.9)
Other	13.0		12.5			(0.5)
Total Intangible assets	268.2	25.6	253.8	26.4	94.6	(14.4)
Investment securities	54.6		53.3			(1.3)
Deferred tax assets	57.8		55.9			(1.9)
Other	7.4		6.9			(0.5)
Allowance for doubtful accounts	(0.2)		(0.2)			(0.0)
Total investments and other assets	119.6	11.4	115.8	12.1	96.9	(3.8)
Total fixed assets	536.9	51.3	514.8	53.6	95.9	(22.2)
Total assets	1,046.3	100.0	959.6	100.0	91.7	(86.7)

Notes

Total assets <Reason for decrease>

Cash payment due to redemption of corporate bonds at maturity (¥40 billion)

Decrease in yen equivalent amount of assets of overseas subsidiaries due to currency exchange fluctuations

2) Consolidated Balance Sheets <Liabilities and Equity>

(billions of yen)

	March 31, 2011	%	June 30, 2011	%	YOY %	Diff.
Notes payable-trade and accounts payable-trade	22.0		23.4			1.4
Bonds and debentures (current portion)	40.0		-			(40.0)
Accounts payable-other/accrued expenses	105.2		99.4			(5.8)
Income tax payable	24.1		6.1			(18.0)
Reserve for sales rebates	23.9		18.1			(5.8)
Other	9.9		11.1			1.2
Total current liabilities	225.1	21.5	158.1	16.5	70.2	(67.0)
Bonds and debentures	80.0		80.0			0.0
Long-term borrowings	259.9		258.4			(1.5)
Deferred tax liabilities	24.8		22.7			(2.1)
Liability for retirement benefits	29.2		31.4			2.2
Other	16.9		16.6			(0.3)
Total long-term liabilities	410.8	39.3	409.1	42.6	99.6	(1.7)
Total liabilities	635.9	60.8	567.2	59.1	89.2	(68.7)
Common stock	45.0		45.0			-
Capital surplus	56.9		56.9			(0.0)
Retained earnings	448.4		439.1			(9.3)
Treasury stock	(39.5)		(39.5)			0.0
Total owners' equity	510.8	48.8	501.5	52.3	98.2	(9.3)
Net unrealized gain (loss) on available-for-sale securities	0.1		(0.5)			(0.6)
Deferred gain (loss) on derivatives under hedge accounting	(0.8)		(0.9)			(0.1)
Foreign currency translation adjustments	(105.9)		(113.9)			(8.0)
Total accumulated other comprehenisve income	(106.6)	(10.2)	(115.4)	(12.0)	-	(8.8)
Stock acquisition rights	0.9	0.1	0.9	0.1	103.5	0.0
Minority interests	5.3	0.5	5.3	0.6	99.4	(0.0)
Total equity	410.4	39.2	392.3	40.9	95.6	(18.0)
Total liabilities and equity	1,046.3	100.0	959.6	100.0	91.7	(86.7)

Notes

Total liabilities <Reason for decrease>

Redemption of corporate bonds at maturity

Total equity <Reason for decrease>

Decrease in yen equivalent amount of equity of overseas subsidiaries due to yen appreciation

7. Changes in Consolidated Quarterly Results

1) Income Statement Data

(billions of yen)

	FY2010				FY2011
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Net sales	204.5	207.8	201.6	155.1	167.3
Cost of sales	43.5	40.6	43.2	40.4	43.0
R&D expenses	36.0	37.8	32.3	38.9	33.7
SG&A expenses	92.1	95.0	83.8	72.1	68.4
Operating income	32.8	34.4	42.2	3.7	22.2
Ordinary income	30.2	32.0	40.6	2.5	21.2
Net income	18.8	21.2	27.4	0.0	13.5
Cash income	32.6	34.2	39.9	13.4	25.9
Comprehensive Income	(0.8)	6.5	18.2	7.3	4.7
Earnings per share (EPS, yen)	65.9	74.3	96.2	0.1	47.4
Cash income per share (Cash EPS, yen)	114.4	119.9	139.9	47.1	90.8

* "Cost of Sales" includes "Provision for (reversal of) sales returns-net."

2) Cash Flow Segment Data

(billions of yen)

	FY2010				FY2011
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Net cash provided by (used in) operating activities	28.2	56.5	20.5	18.1	7.8
Net cash provided by (used in) investing activities	(5.1)	(21.8)	(7.6)	(24.3)	28.2
Net cash provided by (used in) financing activities	(31.1)	(12.3)	(16.3)	(8.3)	(63.1)
Cash and cash equivalents at the end of period	101.4	119.6	113.6	102.8	73.9
Free cash flow	23.9	52.6	14.0	9.8	4.2

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and other expenditures)"

3) Balance Sheet Data

(billions of yen)

	FY2010				FY2011
	June 30	Sep. 30	Dec. 31	March 31	June 30
Total assets	1,065.5	1,064.2	1,054.2	1,046.3	959.6
Liabilities	667.4	659.6	651.3	635.9	567.2
Bonds and debentures	120.0	120.0	120.0	120.0	80.0
Borrowings	279.1	264.3	266.9	259.9	258.4
Equity	398.1	404.6	402.9	410.4	392.3
Shareholders' equity	392.3	398.7	396.9	404.2	386.1
Shareholders' equity ratio to total assets (%)	36.8	37.5	37.6	38.6	40.2
Liabilities ratio（Net DER/times)	0.65	0.51	0.53	0.49	0.56

* "Liabilities ratio（Net DER)" = ("Interest-bearing debt" ("Borrowings" + "Bonds and debentures") - "Cash and cash in banks" - "Short-term investments") / "Shareholders' equity"

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	FY2010				FY2011
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Capital expenditures	3.5	3.7	6.7	9.8	2.7
Property, plant and equipment	2.5	2.8	3.9	5.3	1.8
Intangible assets	1.0	0.9	2.8	4.5	0.9
Depreciation and amortization	11.4	10.7	10.7	10.7	10.5

* "Depreciation and amortization" includes amortization of "Intangible assets."

5) Sales of Major Products

(1) Aricept

		FY2010				FY2011
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Total	Billions JPY	82.9	89.1	75.6	42.7	42.0
East Asia	Billions JPY	26.5	27.0	30.7	26.6	30.0
Japan	Billions JPY	25.3	25.6	29.5	25.1	28.5
U.S.	Billions JPY	50.2	55.9	37.8	9.6	4.7
	[Millions USD]	[545]	[647]	[464]	[133]	[57]
Europe	Billions JPY	5.8	5.8	6.6	6.2	6.8
New Markets & ASEAN	Billions JPY	0.4	0.4	0.5	0.4	0.5

(2) Aciphex/Pariet

		FY2010				FY2011
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Total	Billions JPY	35.3	35.1	38.7	27.9	33.2
East Asia	Billions JPY	16.0	15.7	19.6	11.9	15.5
Japan	Billions JPY	15.1	14.8	18.9	11.4	14.8
U.S.	Billions JPY	17.0	17.0	17.3	14.3	15.8
	[Millions USD]	[185]	[198]	[209]	[174]	[194]
Europe	Billions JPY	1.8	1.9	1.4	1.3	1.4
New Markets & ASEAN	Billions JPY	0.5	0.4	0.4	0.4	0.4

(3) Oncology Related Products

		FY2010				FY2011
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Total	Billions JPY	20.3	19.2	20.2	20.6	24.0
Halaven	Billions JPY	-	-	0.4	1.8	2.6
U.S.	Billions JPY	-	-	0.4	1.8	2.5
	[Millions USD]			[5]	[21]	[31]
Europe	Billions JPY	-	-	-	-	0.1
New Markets & ASEAN	Billions JPY	-	-	-	-	0.0
Aloxi						
U.S.	Billions JPY	8.8	8.5	9.2	8.1	9.7
	[Millions USD]	[96]	[99]	[111]	[98]	[118]
Dacogen						
U.S.	Billions JPY	4.3	4.1	3.8	4.0	4.9
	[Millions USD]	[47]	[47]	[46]	[48]	[60]
Fragmin						
U.S.	Billions JPY	4.3	4.2	3.9	3.8	3.5
	[Millions USD]	[47]	[49]	[48]	[47]	[43]
Other	Billions JPY	2.8	2.4	2.8	3.0	3.3

*Sales of "Other" for the 1Q of FY2011 includes sales of TREAKISYM/Symbenda, which totaled ¥0.8 billion.

(4) Humira

		FY2010				FY2011
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Total	Billions JPY	3.5	3.8	4.5	4.7	5.5
Japan	Billions JPY	2.6	3.0	3.8	3.8	4.6

8. Non-Consolidated Financial Highlights

1) Non-Consolidated Financial Highlights

(1) Income Statement Data

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	YOY %	FY2010
Net sales	116.0	102.9	88.7	464.6
Cost of sales	22.5	22.7	100.6	91.8
R&D expenses	32.8	31.3	95.6	127.4
SG&A expenses	30.8	32.8	106.3	131.8
Operating income	29.9	16.1	53.9	113.5
Ordinary income	27.9	15.6	55.9	106.9
Net income	18.4	10.6	57.9	73.4

* "Cost of sales" includes "Provision for (reversal of) sales returns-net."

(2) Cash Flow Statement Data

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	Diff.	FY2010
Net cash provided by (used in) operating activities	34.2	20.0	(14.2)	128.6
Net cash provided by (used in) investing activities	(3.7)	30.1	33.8	(49.5)
Net cash provided by (used in) financing activities	(31.0)	(63.0)	(32.0)	(67.7)
Cash and cash equivalents at end of period	11.1	10.1	(1.0)	23.1
Free cash flow	31.7	18.2	(13.5)	116.1

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and other expenditures)"

(3) Balance Sheet Data

(billions of yen)

	2011		
	March 31	June 30	Diff.
Total assets	983.7	920.4	(63.4)
Liabilities	456.5	406.0	(50.6)
Bonds and debentures	120.0	80.0	(40.0)
Borrowings	210.0	210.0	-
Equity	527.2	514.4	(12.8)
Shareholders' equity	526.3	513.5	(12.8)
Shareholders' equity ratio to total assets (%)	53.5	55.8	2.3

2) Net Sales Highlights

(billions of yen)

	Three months ended June 30			Full Year
	FY2010	FY2011	YOY %	FY2010
Net sales	116.0	102.9	88.7	464.6
Prescription drugs	77.1	82.2	106.6	311.0
Consumer health care products, etc.	4.6	5.1	111.3	20.9
Industrial property rights and other	21.5	6.8	31.5	79.4
Exports of pharmaceuticals	12.5	8.7	69.7	51.7
Other	0.4	0.2	44.3	1.6

9. Major News Releases

Date	Description
April 2011	• Eisai Enters into Collaborative Research and Development Agreement with PRISM Biolab Corporation Concerning CBP/β-Catenin Inhibiting Compounds <issued on April 4>
	• Morphotek, Inc. Acquires Tumor Targeting Assets from TransMolecular, Inc. <agreement concluded in March 2011> <issued on April 5>
	• Eisai Establishes Sales Subsidiary in Brazil <issued on April 8>
	• Halaven Receives Approval in Japan for the Treatment of Inoperable and Recurrent Breast Cancer <issued on April 22>
	• Abbott Japan and Eisai Receive Approval to Market the Pancreatic Digestive Enzyme Replacement Drug Lipacreon (pancrelipase) in Japan <issued on April 22>
	• U.S. Food and Drug Administration (FDA) Issues Complete Response Letter for Aricept Patch (Donepezil Transdermal System) <issued on April 25>
May	• Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees <issued on May 13>
	• Eisai's Halaven Receives Approval from Swissmedic for Use in Late-stage Metastatic Breast Cancer <issued on May 17>
	• Eisai Oncology to Present New Research on Product Portfolio, Pipeline at ASCO Annual Meeting <issued on May 20>
	• Eisai Receives Approval for Additional Indication of Calcium Channel Blocking Anti-arrhythmic Agent Vasolan for Pediatric Patients in Japan <issued on May 20>
	• Eisai to Donate US$200,000 to American Red Cross in Response to Recent Tornadoes in the United States <issued on May 23>
	• Eisai-University College London Partnership Enters New Phase <issued on May 25>
June	• Phase II Study Results Showed Eisai's Lenvatinib (E7080) Demonstrated an Objective Response Rate of 59% in Advanced Radioiodine-Refractory Differentiated Thyroid Cancer <issued on June 2>
	• Phase III Study of DNA Methylation Inhibitor Dacogen for Injection in Acute Myeloid Leukemia Presented at ASCO <issued on June 7>
	• Information Regarding Voluntary Recall of Chocola BB Sparkling (Vitamin Drink) Due to Mislabeling of Nutritional Information <issued on June 10>
	• Notice on Allocation of Stock Options (Stock Acquisition Rights) <issued on June 21>
	• European Medicines Agency (EMA) Accepts for Review Eisai's Marketing Authorization Application (MAA) for AMPA Receptor Antagonist Perampanel (E2007) <issued on June 24 >
	• Eisai's Antiepileptic Agent Banzel Receives Approval in Canada <issued on June 28>
July	• Abbott Japan and Eisai Receive Approval in Japan for Additional Indication and New Formulation of Humira, a Fully Human Anti-TNF-α Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis <issued on July 1>
	• Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted <issued on July 7>
	• Eisai Enters into Comprehensive Chinese Marketing Agreement with Orion Corprtaion (Finland) Concerning Breast Cancer Treatment Fareston and Parkinson's Disease Treatment Eldepryl <issued on July 13>
	• Eisai Announces U.S. Food and Drug Administration (FDA) Acceptance of supplemental New Drug Application (sNDA) Submission for Dacogen in Acute Myeloid Leukemia <issued on July 14>
	• Eisai Announces Japan Launch of Anticancer Agent Halaven <issued on July 19 >
	• European Medicines Agency (EMA) Accepts Eisai’s License Extension Application for Antiepileptic Agent Zonegran as a Monotherapy <issued on July 28>
	• U.S. Food and Drug Administration (FDA) Provides Response to Perampanel New Drug Application <issued on July 29 >

10. Major R&D Pipeline

1) R&D Pipeline (Japan, United States, Europe)

R&D Pipeline List

	Product Name/Research Code	Additional Indication, etc.*1	Development Stage	Therapeutic Area
New Approval				
○	Halaven (Breast cancer)		(Japan, Switzerland) approved	Oncology and Supportive Care
○	Humira (Juvenile idiopathic arthritis)	AI	(Japan) approved	Vascular and Immunological Reaction
○	Vasolan (Pediatric dosage and administration)	ADA	(Japan) approved	Vascular and Immunological Reaction
○	Warfarin (Granules)	AF	(Japan) approved	Vascular and Immunological Reaction
Under Review/Preparing for Submission				
○	E2007 (Partial-onset epilepsy)		(EU) under review (US) preparing for resubmission*2	Neurology
	SEP-190 (Insomnia)		(Japan) under review	Neurology
	E7040 (Transcatheter arterial embolization (TAE) in patients with hepatocellular carcinoma (HCC))		(Japan) under review	Oncology and Supportive Care
○	Zonegran (Monotherapy for epilepsy)	AI	(EU) under review	Neurology
○	Dacogen (Acute myeloid leukemia (AML))	AI	(US) under review	Oncology and Supportive Care
○	Warfarin (Granules pediatric dosage and administration)	ADA	(Japan) under review	Vascular and Immunological Reaction
	Pariet/Aciphex (Extended-release 50 mg formulation)	AF	(US/EU) under review	Gastrointestinal Disorders
	Inovelon (Oral suspension)	AF	(EU) under review	Neurology
Clinical				
○	E2007 (Generalized epilepsy)		(Global Development Program) PIII	Neurology
	E2080 (Lennox-Gastaut syndrome (LGS))		(Japan) PIII	Neurology
	E5564 (Severe sepsis)		(Global Development Program) PIII	Vascular and Immunological Reaction
	E6014 (Oral mucositis)		(US) PIII	Oncology and Supportive Care
	E7080 (Thyroid cancer)		(Global Development Program) PIII	Oncology and Supportive Care
	Halaven (Sarcoma)		(US) PIII (EU) PII	Oncology and Supportive Care
	MORAb-003 (Platinum-sensitive ovarian cancer)		(Global Development Program) PIII	Oncology and Supportive Care
	T-614 (Rheumatoid arthritis)		(Japan) PIII	Vascular and Immunological Reaction
	Aricept (Lewy body dementia)	AI	(Japan) PIII	Neurology
	Zonegran (Pediatric epilepsy)	AI	(EU) PIII	Neurology
○	Ontak (Peripheral T-cell lymphoma (PTCL))	AI	(US) PIII	Oncology and Supportive Care
	Humira (Inhibition of structural damage of joints)	AI	(Japan) PIII	Vascular and Immunological Reaction
	E0302 (Amyotrophic lateral sclerosis (ALS))		(Japan) PII/III	Neurology
○	MORAb-003 (Platinum-resistant ovarian cancer)		(US/EU) PII/III	Oncology and Supportive Care
	AS-3201 (Diabetic neuropathy)		(US/EU) PII/III	Neurology
	Humira (Ulcerative colitis)	AI	(Japan) PII/III	Vascular and Immunological Reaction
○	Pariet (Prevention of recurrence of gastric and duodenal ulcers during treatment with low-dosage aspirin)	AI	(Japan) PII/III	Gastrointestinal Disorders
	E2007 (Partial-onset epilepsy)		(Japan) PII	Neurology
	E2007 (Neuropathic pain)		(US/EU) PII	Neurology
	E2007 (Multiple sclerosis)		(EU) PII	Neurology
	E2007 (Migraine prophylaxis)		(US) PII	Neurology
	E5501 (Idiopathic thrombocytopenic purpura (ITP))		(US) PII	Oncology and Supportive Care
	E5501 (Thrombocytopenia associated with liver disease (TLD))		(US) PII	Oncology and Supportive Care
	E5555 (Acute coronary syndrome)		(Japan/US/EU) PII	Vascular and Immunological Reaction
	E5555 (Atherothrombosis)		(Japan/US/EU) PII	Vascular and Immunological Reaction
	E6201 (Psoriasis)		(US/EU) PII	Vascular and Immunological Reaction
	E7080 (Endometrial cancer)		(US/EU) PII	Oncology and Supportive Care
	E7080 (Melanoma)		(US/EU) PII	Oncology and Supportive Care
	E7080 (Glioma)		(US) PII	Oncology and Supportive Care
	Halaven (Non-small cell lung cancer)		(US) PII	Oncology and Supportive Care
	Halaven (Prostate cancer)		(US/EU) PII	Oncology and Supportive Care
	E7820 (Colorectal cancer)		(US) PII	Oncology and Supportive Care
	E7850 (Prostate cancer, etc)		(US) PII	Oncology and Supportive Care
	MORAb-003 (Non-small cell lung cancer)		(US) PII	Oncology and Supportive Care
○	MORAb-004 (Melanoma)		(US) PII	Oncology and Supportive Care
	MORAb-009 (Mesothelioma)		(US/EU) PII	Oncology and Supportive Care
	Ontak (Melanoma)	AI	(US) PII	Oncology and Supportive Care
○	Dacogen (Pediatric acute myeloid leukemia (AML))	AI	(US) PII	Oncology and Supportive Care
	Pariet (Functional dyspepsia)	AI	(Japan) PII	Gastrointestinal Disorders
	Aricept (Higher dose 23 mg tablet)	ADA, AF	(Japan) PII	Neurology

*1 AI：Additional Indication, ADA：Additional Dosage & Administration, AF：Additional Formulation P : Clinical phase

*2 Eisai submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in May 2011. Upon preliminary review, the FDA has requested additional information including reformatting of some datasets. The company is working to provide the information requested for resubmission.

○ Development progress from April 2011 onwards

(1) Oncology and Supportive Care

Product Name: **Halaven** Research Code: **E7389** Generic name: **eribulin mesylate** (Anticancer agent/microtubule dynamics inhibitor)

Description: A synthetic analog of halichondrin B derived from a marine sponge. Believed to exert an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Currently being investigated as a potential treatment for breast cancer and various other solid tumors. Received approval in 34 countries including the United States, Singapore, the European Union (EU), Switzerland, and Japan. In addition, a Phase III study investigating the potential of the agent as a second-line treatment for recurrent and metastatic breast cancer is ongoing in the United States and Europe.				
	Breast cancer	○ Japan: approved (April 2011) ○ Switzerland: approved (May 2011)		Inj.
	Non-small cell lung cancer	US: PII		Inj.
	Prostate cancer	US: PII EU: PII		Inj.
	Sarcoma	US: PIII EU: PII		Inj.

Research Code: **E7820** (Anticancer agent/angiogenesis inhibitor that suppresses alpha 2 integrin expression)

Description: An angiogenesis inhibitor that suppresses the expression of alpha 2 integrin, a vascular endothelial cell adhesion molecule.				
	Colorectal cancer	US: PII		Oral

Research Code: **E7080** (Anticancer agent/VEGF receptor tyrosine kinase inhibitor/multi-kinase inhibitor)

Description: An anti-angiogenic agent that inhibits tyrosine kinase of the VEGF receptor, VEGFR2, and a number of other types of kinase involved in angiogenesis and tumor proliferation. Currently being investigated as a potential treatment for various solid tumors.				
	Thyroid cancer	Global Development Program PIII	Submission Target FY2013	Oral
	Endometrial cancer	US: PII EU: PII		Oral
	Melanoma	US: PII EU: PII		Oral
	Glioma	US: PII		Oral

Research Code: **MORAb-003** Generic name: **farletuzumab** (Anticancer agent/monoclonal antibody)

Description: A humanized IgG1 monoclonal antibody that targets folate receptor alpha (FRA). Expected to exhibit an antitumor effect against carcinomas that over-express FRA. A Phase III study for platinum-sensitive ovarian cancer as well as a Phase II/III study for platinum-resistant ovarian cancer were initiated in Europe and the United States.				
	Platinum-sensitive ovarian cancer	Global Development Program: PIII	Submission Target FY2012	Inj.
○	Platinum-resistant ovarian cancer	US: PII/III EU: PII/III		Inj.
	Non-small cell lung cancer	US: PII		Inj.

Research Code: **MORAb-004** (Anticancer agent/monoclonal antibody)

Description: A humanized lgG1 monoclonal antibody that targets TEM-1 (endosialin). Expected to exhibit an antitumor effect against carcinomas that express endosialin.				
○	Melanoma	US: PII		Inj.

○ Development progress from April 2011 onwards

Research Code: **MORAb-009** Generic name: **amatuximab** (Anticancer agent/monoclonal antibody)

Description: A chimeric IgG1 monoclonal antibody that blocks the function of mesothelin. Expected to exhibit an antitumor effect against carcinomas that express mesothelin.		
Mesothelioma	US: PII EU: PII	Inj.

Product Name: **Dacogen** Research Code: **E7373** Generic name: **decitabine** (DNA methylation inhibitor)

Description: Induces cell differentiation through inhibition of DNA methylation. Currently approved in the United States for the treatment of myelodysplastic syndromes (MDS).			
○	**Additional Indication:** Acute myeloid leukemia (AML)	US: submitted (May 2011) accepted (July 2011)	Inj.
○	**Additional Indication :** Pediatric acute myeloid leukemia (AML)	US: PII	Inj.

Research Code: **E7850** Generic Name: **irofulven** (Anticancer agent/DNA synthesis inhibitor)

Description: Expected to exhibit an anticancer effect against various solid tumors by inhibiting DNA synthesis.		
Prostate cancer, etc.	US: PII	Inj.

Research Code: **E5501/AKR-501** (Treatment for thrombocytopenia/thrombopoietin receptor agonist)

Description: A novel, oral thrombopoietin receptor agonist that stimulates platelet production. Expected to exhibit effects against conditions that are associated with thrombocytopenia.			
Idiopathic thrombocytopenic purpura (ITP)	US: PII	Submission Target FY2013	Oral
Thrombocytopenia associated with liver disease (TLD)	US: PII		Oral

Research Code: **E6014** Generic name: **glutamine** (Oral mucositis/glutamine oral suspension)

Description: A topical, oral glutamine suspension for the treatment of chemotherapy-induced mucositis.		
Oral mucositis	US: PIII	**Oral Suspension**

Product Name: **Ontak** Research Code: **E7272** Generic name: **denileukin diftitox**
(Anticancer agent/interleukin-2 diphtheria toxin fusion protein)

Description: A fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxins. It specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxins that have entered cells to inhibit protein synthesis. The agent is already approved in the United States as a treatment for CD25 (a component of the IL-2 receptor) positive cutaneous T-cell lymphoma.			
○	**Additional Indication:** Peripheral T-cell lymphoma (PTCL)	US: PIII	Inj.
	Additional Indication: Melanoma	US: PII	Inj.

Research Code: **E7040** (Embolic bead/medical device)

Description: A hydrophilic microspherical particle produced from a polyvinyl alcohol polymer. An embolic bead that is injected through a catheter to physically and selectively embolize targeted blood vessels. Microscopic and uniformly spherical in shape, it allows for precise embolization of targeted vessels based on vascular diameter and tumor size.		
Transcatheter arterial embolization (TAE) in patients with hepatocellular carcinoma (HCC)	Japan: under review (December 2010)	Embolic Agent

○ Development progress from April 2011 onwards

(2) Neurology

Product Name: **Aricept** Research Code: **E2020** Generic name: **donepezil** (Anti-Alzheimer's agent)

Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting its breakdown by the enzyme acetylcholinesterase, thereby slowing the overall progression of symptoms associated with Alzheimer's disease (AD). Currently approved in more than 90 countries around the world for the treatment of mild to moderate AD. It is also approved as a treatment for patients with severe AD in countries including the United States, Canada, Japan, and some Asian and South/Central American countries.			
Additional Indication: Lewy body dementia	Japan: PIII	Submission Target FY2012	Oral
Additional Dosage & Administration, Formulation: Higher dose 23 mg tablet	Japan: PII		Oral

Research Code: **E2007** Generic name: **perampanel** (AMPA receptor antagonist)

Description: A selective AMPA-subtype glutamate receptor antagonist for the treatment of a variety of neurological disorders. Clinical studies investigating the potential of the agent as an adjunctive treatment for partial-onset seizures as well as a treatment for generalized seizures in patients with epilepsy are currently underway. Further studies are also planned for perampanel in monotherapy for partial-onset seizures and other forms of epilepsy such as Lennox-Gastaut syndrome (LGS).		
Partial-onset epilepsy	○ EU: submitted (May 2011) accepted (June 2011) ○ US: preparing for resubmission Japan : PII	Oral
Generalized epilepsy	Global ○ Development Program PIII	Oral
Neuropathic pain	US: PII EU: PII	Oral
Multiple sclerosis	EU: PII	Oral
Migraine prophylaxis	US: PII	Oral

・ Eisai submitted a New Drug Application (NDA) to the FDA in May 2011. Upon preliminary review, the FDA has requested additional information including reformatting of some datasets. The company is currently working to provide the information requested for resubmission.

Research Code: **AS-3201** Generic name: **ranirestat** (Treatment for diabetic complications/aldose reductase inhibitor)

Description: An aldose reductase inhibitor that is believed to reduce intracellular accumulation of sorbitol. Currently being investigated as a potential treatment for diabetic neuropathy, one of the most common diabetic complications.		
Diabetic neuropathy	US: PII/III EU: PII/III	Oral

Product Name: **Zonegran** Research Code: **E2090** Generic name: **zonisamide** (Anti-epileptic agent)

Description: Believed to exhibit a broad anti-epileptic spectrum and is well-tolerated. Currently indicated as an adjunctive therapy in the treatment of patients with partial-onset seizures.			
○ **Additional Indication:** Monotherapy for epilepsy	EU: submitted (June 2011) Accepted (July 2011)		Oral
Additional Indication: Pediatric epilepsy	EU: PIII	Submission Target FY2011	Oral

Research Code: **E0302** Generic name: **mecobalamin** (Amyotrophic lateral sclerosis)

Description: A mecobalamin (vitamin B_{12} coenzyme) formulation. Restores damaged peripheral nerves and is widely used for the treatment of peripheral neuropathy. Currently being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS).		
Amyotrophic lateral sclerosis (ALS)	Japan: PII/III	Inj.

Research Code: **SEP-190** Generic name: **eszopiclone** (Treatment for insomnia/$GABA_A$ receptor agonist)

Description: A non-benzodiazepine type allosteric $GABA_A$ receptor agonist that may help patients with transient or short-term insomnia, as well as insomnia in the elderly.		
Insomnia	Japan: under review (November 2010)	Oral

○ Development progress from April 2011 onwards

Product Name: **Inovelon(EU)／Banzel(US)** Research Code: **E2080** Generic name: **rufinamide** (Anti-epileptic agent)

Description: A triazole derivative that is structurally unrelated to currently marketed antiepileptic drugs (AEDs). It is believed to regulate the activity of sodium channels in the brain which carry excessive electrical charges. The agent is approved in Europe (under the product name Inovelon) and the United States (under the product name Banzel) as an adjunctive therapy for Lennox-Gastaut syndrome (LGS).			
Additional Formulation: Oral suspension	EU: submitted (September 2010), accepted (October 2010)		Oral
Adjunctive therapy for LGS	Japan: PIII	Submission Target FY2012	Oral

(3) Vascular and Immunological Reaction

Product Name: **Humira** Research Code: **D2E7** Generic name: **adalimumab** (Fully human anti-TNF-alpha monoclonal antibody)

Description: A fully human anti-TNF-alpha monoclonal antibody that neutralizes the activity of tumor necrosis factor alpha (TNF-alpha), a type of cytokine that plays a central role in inflammatory reactions in patients with autoimmune diseases. Approved in Japan for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, and juvenile idiopathic arthritis.			
○ **Additional Indication:** Juvenile idiopathic arthritis	Japan: approved (July 2011)		Inj.
Additional Indication: Inhibition of structural damage of joints	Japan: PIII	Submission Target FY2011	Inj.
Additional Indication: Ulcerative colitis	Japan: PII/III	Submission Target FY2011	Inj.

Research Code: **E5564** Generic name: **eritoran** (Severe sepsis/endotoxin antagonist)

Description: Exhibits endotoxin antagonist effects that inhibit isolation of inflammatory cytokines. Suppresses various clinical conditions caused by endotoxins.		
Severe sepsis	Global Development Program: PIII	Inj.

.

Research Code: **E5555** (Thrombin receptor antagonist)

Description: Selectively binds to the thrombin receptor (PAR-1) and inhibits platelet aggregation and vascular smooth muscle cell proliferation by suppressing thrombin-mediated cellular activation.		
Acute coronary syndrome	US: PII EU: PII Japan: PII	Oral
Atherothrombosis	US: PII EU: PII Japan: PII	Oral

Research Code: **E6201** (Novel MEK-1/MEKK-1 kinase inhibitor)

Description: A novel MEK-1/MEKK-1 kinase inhibitor. Expected to inhibit inflammatory cellular signaling as well as overgrowth of epidermal cells in patients with psoriasis.		
Psoriasis	US: PII EU: PII	Topical

Research Code: **T-614** Generic name: **iguratimod** (Rheumatoid arthritis)

Description: Suppresses inflammatory cytokine production and immunoglobulin production. Expected to exhibit effects against rheumatoid arthritis.			
Rheumatoid arthritis	Japan: PIII	Submission Target FY2011	Oral

○ Development progress from April 2011 onwards

Product Name: **Warfarin** Generic name: **warfarin potassium** (Oral anticoagulant)

Description: Exhibits anticoagulant effects by antagonizing vitamin K and inhibiting the production of blood clotting factors. Widely used for the treatment and prevention of thromboembolisms in adults. An application seeking approval for pediatric use of the newly approved granules formulation was submitted in Japan after the Japanese Ministry of Health, Labour and Welfare's Study Group on Unapproved and Off Label Drugs of High Medical Need designated the agent as a drug that can provide significant clinical benefits to pediatric patients.			
○	**Additional Formulation:** Granules	Japan: approved (July 2011)	Oral
○	**Additional Dosage & Administration:** Granules pediatric dosage & administration	Japan: submitted (July 2011)	Oral

Product Name: **Vasolan** Generic name: **verapamil** (Calcium channel blocking anti-arrhythmic agent)

Description: Slows cardiac excitation and regulates tachyarrhythmia by blocking calcium channels. Also exhibits coronary dilating and peripheral vasodilator action and is widely used as a treatment for ischemic heart disease and tachyarrhythmia in adults. An application seeking approval for pediatric dosage and administration was approved in Japan after the Japanese Ministry of Health, Labour and Welfare's Study Group on Unapproved and Off Label Drugs of High Medical Need designated the agent as a drug that can provide significant clinical benefits to pediatric patients.			
○	**Additional Dosage & Administration:** Pediatric dosage & administration	Japan: approved (May 2011)	Oral Inj.

(4) Gastrointestinal Disorders

Product Name: **Pariet/Aciphex** Research Code: **E3810** Generic name: **rabeprazole** (Proton pump inhibitor)

Description: A proton pump inhibitor approved for the treatment of gastric and duodenal ulcers, reflux esophagitis and eradication of *Helicobacter pylori* infections, etc.			
	Additional Formulation: Extended-release 50 mg formulation	US: submitted (March 2010), accepted (June 2010) EU: submitted (March 2010), accepted (September 2010)	Oral
○	**Additional Indication:** Prevention of recurrence of gastric and duodenal ulcers during treatment with low-dosage aspirin	Japan: PII/III	Oral
	Additional Indication: Functional dyspepsia	Japan: PII	Oral

・ Eisai received a Complete Response Letter from the FDA in January 2011 concerning the New Drug Application (NDA) submitted in the United States for the Aciphex extended-release 50mg formulation. The company is currently working closely with the FDA to address the requirements of the Complete Response Letter for the approval of the new formulation.

○ Development progress from April 2011 onwards

2) R&D Pipeline (Asia)

Product Name: **Glufast** Generic name: **mitiglinide** (Rapid-acting insulin secretagogue agent)

Description: By selectively binding to sulfonylurea receptors in pancreatic beta cells, it accelerates insulin release, resulting in the reduction of blood glucose. (In-licensed from Kissei Pharmaceutical Co., Ltd.)		
Type 2 diabetes mellitus	currently marketed: Thailand approved: Philippines under review: Indonesia, Malaysia	Oral

Product Name: **Gasmotin** Generic name: **mosapride** (Gastroprokinetic agent)

Description: A selective serotonin 5-HT_4 receptor agonist that exhibits gastroprokinetic and gastric evacuation effects by enhancing acetylcholine release. (In-licensed from Dainippon Sumitomo Pharma Co., Ltd.)		
Gastroprokinetic agent	currently marketed: Thailand, Philippines approved: Vietnam under review: Malaysia, Myanmar, Laos, Cambodia	Oral

Generic name: **clevudine** (Anti-chronic hepatitis B agent)

Description: An antiviral drug that exerts an anti-HBV effect by inhibiting DNA polymerase. (In-licensed from Bukwang Pharmaceutical Co., Ltd.)		
Chronic hepatitis B	currently marketed: Philippines (Product Name: Revovir) under review: Indonesia, Thailand, Vietnam, India, China	Oral

Product Name: **Urief** Generic name: **silodosin** (Treatment for dysuria associated with benign prostatic hyperplasia)

Description: A selective alpha 1A-adrenergic receptor antagonist. By selectively blocking alpha 1A-adrenergic receptors that are found primarily in the prostate gland, it reduces urethral resistance by relaxing certain prostate gland muscles, thereby improving dysuria associated with benign prostatic hyperplasia (BPH). (In-licensed from Kissei Pharmaceutical Co., Ltd.)		
Dysuria associated with BPH	under review: Singapore, Thailand	Oral

Generic name: **cinitapride** (Gastroprokinetic agent)

Description: By stimulating 5-HT_2 and 5-HT_4 receptors found in the gastrointestinal tract, the agent increases acetylcholine release and improves upper gastrointestinal motility. Its antidopaminergic activity also helps stimulate the release of acetylcholine by blocking dopamine receptors, thereby improving upper gastrointestinal function. (In-licensed from Almirall, S.A.)		
Functional dyspepsia	clinical development ongoing: China (PIII)	Oral

○ Development progress from April 2011 onwards